Metabolic Profiling to Assess Response to Targeted and Immune Therapy in Melanoma

被引:2
作者
Farah, Chantale [1 ]
Mignion, Lionel [2 ]
Jordan, Benedicte F. [1 ,2 ]
机构
[1] Univ Catholique Louvain UCLouvain, Louvain Drug Res Inst, Biomed Magnet Resonance Res Grp, B-1200 Brussels, Belgium
[2] Univ Catholique Louvain UCLouvain, Louvain Drug Res Inst LDRI, Nucl & Electron Spin Technol NEST Platform, B-1200 Brussels, Belgium
关键词
melanoma; metabolic imaging; response to treatment; BRAF-targeted therapy; immune checkpoint inhibitors; BRAF-MUTANT MELANOMA; MEK INHIBITION; TUMOR MICROENVIRONMENT; ACQUIRED-RESISTANCE; GLUCOSE-METABOLISM; ANTITUMOR-ACTIVITY; CLINICAL-RESPONSE; IMPROVED SURVIVAL; CELL-ACTIVATION; F-18-FDG PET/CT;
D O I
10.3390/ijms25031725
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
There is currently no consensus to determine which advanced melanoma patients will benefit from targeted therapy, immunotherapy, or a combination of both, highlighting the critical need to identify early-response biomarkers to advanced melanoma therapy. The goal of this review is to provide scientific rationale to highlight the potential role of metabolic imaging to assess response to targeted and/or immune therapy in melanoma cancer. For that purpose, a brief overview of current melanoma treatments is provided. Then, current knowledge with respect to melanoma metabolism is described with an emphasis on major crosstalks between melanoma cell metabolism and signaling pathways involved in BRAF-targeted therapy as well as in immune checkpoint inhibition therapies. Finally, preclinical and clinical studies using metabolic imaging and/or profiling to assess response to melanoma treatment are summarized with a particular focus on PET (Positron Emission Tomography) imaging and 13C-MRS (Magnetic Resonance Spectroscopy) methods.
引用
收藏
页数:21
相关论文
共 183 条
  • [1] Metabolic imaging using hyperpolarized 13C-pyruvate to assess sensitivity to the B-Raf inhibitor vemurafenib in melanoma cells and xenografts
    Acciardo, Stefania
    Mignion, Lionel
    Lacomblez, Estelle
    Schoonjans, Celine
    Joudiou, Nicolas
    Gourgue, Florian
    Bouzin, Caroline
    Baurain, Jean-Francois
    Gallez, Bernard
    Jordan, Benedicte F.
    [J]. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2020, 24 (02) : 1934 - 1944
  • [2] Hyperpolarized 1-[13C]-Pyruvate Magnetic Resonance Imaging Detects an Early Metabolic Response to Androgen Ablation Therapy in Prostate Cancer
    Aggarwal, Rahul
    Vigneron, Daniel B.
    Kurhanewicz, John
    [J]. EUROPEAN UROLOGY, 2017, 72 (06) : 1028 - 1029
  • [3] Hyperpolarized 13C Lactate, Pyruvate, and Alanine: Noninvasive Biomarkers for Prostate Cancer Detection and Grading
    Albers, Mark J.
    Bok, Robert
    Chen, Albert P.
    Cunningham, Charles H.
    Zierhut, Matt L.
    Zhang, Vickie Yi
    Kohler, Susan J.
    Tropp, James
    Hurd, Ralph E.
    Yen, Yi-Fen
    Nelson, Sarah J.
    Vigneron, Daniel B.
    Kurhanewicz, John
    [J]. CANCER RESEARCH, 2008, 68 (20) : 8607 - 8615
  • [4] Anderson C M, 1995, Oncology (Williston Park), V9, P1149
  • [5] A guide to 13C metabolic flux analysis for the cancer biologist
    Antoniewicz, Maciek R.
    [J]. EXPERIMENTAL AND MOLECULAR MEDICINE, 2018, 50 : 1 - 13
  • [6] Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab
    Anwar, Hoda
    Sachpekidis, Christos
    Winkler, Julia
    Kopp-Schneider, Annette
    Haberkorn, Uwe
    Hassel, Jessica C.
    Dimitrakopoulou-Strauss, Antonia
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (03) : 376 - 383
  • [7] PD1 signal transduction pathways in T cells
    Arasanz, Hugo
    Gato-Canas, Maria
    Zuazo, Miren
    Ibanez-Vea, Maria
    Breckpot, Karine
    Kochan, Grazyna
    Escors, David
    [J]. ONCOTARGET, 2017, 8 (31) : 51936 - 51945
  • [8] The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study
    Ascierto, Paolo A.
    Bastholt, Lars
    Ferrucci, Pier F.
    Hansson, Johan
    Marquez Rodas, Ivan
    Payne, Miranda
    Robert, Caroline
    Thomas, Luc
    Utikal, Jochen S.
    Wolter, Pascal
    Kudlac, Amber
    Tuson, Harriet
    McKendrick, Jan
    [J]. MELANOMA RESEARCH, 2018, 28 (04) : 333 - 340
  • [9] Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
    Atefi, Mohammad
    Avramis, Earl
    Lassen, Amanda
    Wong, Deborah J. L.
    Robert, Lidia
    Foulad, David
    Cerniglia, Michael
    Titz, Bjoern
    Chodon, Thinle
    Graeber, Thomas G.
    Comin-Anduix, Begonya
    Ribas, Antoni
    [J]. CLINICAL CANCER RESEARCH, 2014, 20 (13) : 3446 - 3457
  • [10] Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134
    Atkins, Michael B.
    Lee, Sandra J.
    Chmielowski, Bartosz
    Tarhini, Ahmad A.
    Cohen, Gary I.
    Truong, Thach-Giao
    Moon, Helen H.
    Davar, Diwakar
    O'Rourke, Mark
    Stephenson, Joseph J.
    Curti, Brendan D.
    Urba, Walter J.
    Brell, Joanna M.
    Funchain, Pauline
    Kendra, Kari L.
    Ikeguchi, Alexandra P.
    Jaslowski, Anthony
    Bane, Charles L.
    Taylor, Mark A.
    Bajaj, Madhuri
    Conry, Robert M.
    Ellis, Robert J.
    Logan, Theodore F.
    Laudi, Noel
    Sosman, Jeffrey A.
    Crockett, David G.
    Pecora, Andrew L.
    Okazaki, Ian J.
    Reganti, Sowjanya
    Chandra, Sunandana
    Guild, Samantha
    Chen, Helen X.
    Streicher, Howard Z.
    Wolchok, Jedd D.
    Ribas, Antoni
    Kirkwood, John M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (02) : 186 - +